Aligos Therapeutics, Inc. (ALGS) compared with its closest peers (EXOZ, INMB, INKT, TIL, SCLX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| eXoZymes, Inc. (EXOZ) | $68.45M | -9.7 |
| INmune Bio, Inc. (INMB) | $63.83M | -0.8 |
| MiNK Therapeutics, Inc. (INKT) | $62.21M | -3.8 |
| Instil Bio, Inc. (TIL) | $51.81M | -1.0 |
| Scilex Holding Company (SCLX) | $48.07M | -0.3 |
| Metagenomi, Inc. Common Stock (MGX) | $46.09M | -0.7 |
| Elutia Inc. (ELUT) | $37.98M | 0.8 |
| Quince Therapeutics, Inc. (QNCX) | $33.82M | -2.0 |
| Dyadic International, Inc. (DYAI) | $25.49M | — |
| CEL-SCI Corporation (CVM) | $25.15M | -1.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
ALGS overview · ALGS earnings · ALGS financials · ALGS KPIs · ALGS investor relations · ALGS ownership · ALGS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.